drugset
drugset / Trial / NCT02738905

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

NCT02738905 ↗

Phase 0 Withdrawn Jason Stubbs, MD American Heart Association · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if rifaximin reduces serum trimethylamine-N-oxide (TMAO) levels in patients with end-stage renal disease.

Timeline

Start
2016-01
Primary completion
2019-02-26
Completion
2019-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 550 mg Oral

Indications

end stage renal failure